Results of multicenter testing of PIK3CA somatic mutations in hormone-receptor positive HER2-negative advanced breast cancer

Aim: Activating somatic mutations in p110α catalytic subunit of PIK3-kinase (PIK3CA) are present in about 40% of breast cancers (BC), and are involved in oncogenesis and cancer growth. PIK3CA inhibitor therapy is approved for patients with advanced HR+/HER2- endocrine-resistant BC with somatic PIK3C...

Descripció completa

Dades bibliogràfiques

Autors principals:	Snježana Ramić, Melita Perić-Balja, Ita Hadžisejić, Zlatko Marušić, Valerija Blažičević, Snježana Tomić
Format:	Artigo
Idioma:	Inglês
Publicat:	University Hospital for Tumors 2023-01-01
Col·lecció:	Libri Oncologici
Matèries:	breast cancer PIK3CA mutation
Accés en línia:	https://hrcak.srce.hr/file/440489
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!